Genmab — Januar 2018
-
God morgen.
-
Ritzau kan noget med overskrifter og god morgen https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=466310013&sourcecode=ddk
-
God morgen.
-
Copy/paste fra Børsen.
-
-
Jeg mente nu den anden vej rundt, men fik udtrykt mig lidt uklart
-
-
Novartis intends to transition the commercial availability of Arzerra to limited availability via compassionate use programs for treatment of CLL in non-US markets. Novartis will continue to market for CLL in the US
Novartis will work with regulatory authorities to establish compassionate use programs so that patients benefitting from Arzerra can remain on treatment
Genmab receives USD 50 million from Novartis as payment for lost potential milestones and royalties
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind